Clinical Trial Update: Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ibritinib in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic adenocarcinoma; study completed with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Ibrutinib (ibrutinib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Margaret Tempero | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-07-16